MorphoSys Hopes FDA Incentive Programs Can Boost Proprietary Plans
This article was originally published in The Pink Sheet Daily
Executive Summary
MorphoSys’s ambition to grow a proprietary pipeline got a boost with FDA giving its lead compound MOR208 fast track status for the treatment of relapsed or refractory diffuse large B-cell lymphoma.